{"doi":"10.1093/ibd/izab159","title":"Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis","abstract":"To the Editors, We write to report a case of successful use of vedolizumab in a patient with immune checkpoint inhibitor colitis and concurrent clostridium difficile infection. Consent was provided by the patient. Our patient is a 68-year-old female with metastatic squamous cell carcinoma of the bladder complicated treated with resection and lung metastases treated with chemotherapy referred for diarrhea. She had recently been found to have local progression of lung lesion on routine imaging and started on pembrolizumab. She completed six cycles with excellent tumor response until she developed watery diarrhea and abdominal pain 3 months after starting therapy. Initial imaging was normal, and stool was positive for C. difficile. She was started on oral vancomycin but required admission for dehydration despite therapy. There was minimal improvement after therapy, and follow-up testing was negative. Esophagogastroduodenoscopy (EGD) and colonoscopy were performed at that point with duodenitis and colitis. The biopsies were consistent with checkpoint-inhibitor enterocolitis (ICI-EC). She improved with oral prednisone but had recurrence of symptoms with weaning of systemic steroids; thus EGD and colonoscopy were repeated while on steroids and revealed ongoing inflammation. She was then started on vedolizumab (VDZ) induction therapy steroids were tapered off over six weeks. Clinical symptoms improved; however, colonoscopy at week 14 had similar findings to prior evaluation on steroids. Therefore, she continued on maintenance therapy with vedolizumab. She was also found to have new osteopenia and spinal compression fracture due to steroids.","journal":"Inflammatory Bowel Diseases","year":2021,"id":211188,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9511,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":762160,"name":"E Förster","orcid":"0000-0002-2004-5017","position":1,"is_corresponding":false},{"id":800118,"name":"Molly L. Stone","orcid":"0000-0002-0663-0092","position":0,"is_corresponding":true}],"reference_count":4,"raw_metadata":null,"created_at":"2026-07-18T23:52:16.049481Z","pmid":"34244730","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}